(S023) Ultrasound Tissue Characterization of Breast Fibrosis Following Hypofractionated Breast Radiotherapy

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This is the first prospective imaging study to objectively document normal-tissue toxicity in patients treated with hypofractionation breast RT using ultrasonography tissue characterization. Contrary to the criticism, patients receiving hypofractionation RT recovered better and experienced less late toxicity at the 1-year follow-up.

Xiaofeng Yang, Mylin Torres, MD, Simone Henry, Donna Mister, Tatiana Han, Walter Curran, Tian Liu; Emory University

PURPOSE: Hypofractionation whole-breast radiotherapy (RT) following conservation surgery has been used in many institutions for several decades. However, the hypofractionation regimen has not been widely accepted in the United States. Criticism has focused on concerns about late normal-tissue effects. The purpose of this study is to evaluate breast fibrosis in patients receiving hypofractionated RT using quantitative ultrasound tissue characterization.

MATERIALS AND METHODS: Twenty postlumpectomy women were enrolled in a prospective, longitudinal ultrasound imaging study to examine the development of RT-induced normal-tissue toxicity. Each received simultaneous integrated boost (SIB) RT (40 Gy plus simultaneous cavity boost to 48 Gy in 15 fractions). A baseline ultrasound scan was performed 1 week prior to RT, plus one scan during RT, followed by evaluation at the 1-year follow-up. Patients were imaged with 10-MHz ultrasonography at the 12, 3, 6, and 9 o’clock positions of the breast. To compensate for individual variation, scans taken on the untreated contralateral breast served as a control. Ultrasonography parameters, including skin thickness, Pearson coefficient, and midband fit, were calculated to quantify cutaneous and glandular tissue toxicity. Quantitative ultrasonography parameters were generated by normalizing to the corresponding contralateral breast. Ultrasonography findings were compared with clinical assessments based on the Radiation Therapy Oncology Group (RTOG) toxicity scheme.

RESULTS: Based on the ultrasonography measurements, 50% to 60% of patients developed mild to moderate late toxicity (fibrosis) 1-year post-RT. For the 20 patients, the average skin thickness ratios were 1.23 prior to RT, 1.33 during RT, and 1.37 at the 1-year follow-up. Prior to RT, the diseased breast experienced 23% greater skin thickening secondary to postsurgical changes. The midband fit ratios were 1.12 prior to RT, 1.70 during RT, and 2.45 1-year post-RT. The Pearson ratios were 0.92 prior to RT, 0.78 during RT, and 0.63 1-year post-RT. Increased skin thickness and midband fit values correlated with increased cutaneous toxicity assessed using RTOG scores (P < .05). The ultrasonography findings were consistent with the clinical assessments: 60% developed RTOG grade 1 toxicity, and 10% developed grade 2 toxicity at 1 year.

CONCLUSIONS: This is the first prospective imaging study to objectively document normal-tissue toxicity in patients treated with hypofractionation breast RT using ultrasonography tissue characterization. Contrary to the criticism, patients receiving hypofractionation RT recovered better and experienced less late toxicity at the 1-year follow-up. With this noninvasive ultrasonography technology, physicians can objectively compare the late effects of hypofractionation with the standard regimen and gain a better understanding of treatment responses in individual patients. 

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Related Content